A study investigating the absorption and food effect of different tablet formulations of JNJ-77242113, a new compound in the treatment of inflammatory diseases
Phase 1
- Conditions
- Inflammatory ConditionsTherapeutic area: Diseases [C] - Immune System Diseases [C20]
- Registration Number
- CTIS2023-504720-26-00
- Lead Sponsor
- Janssen - Cilag International
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method